β¨ Medicines Consent Notices
3246
NEW ZEALAND GAZETTE, No. 109
21 SEPTEMBER 2006
Schedule
Product: Baraclude
Active Ingredient: Entecavir 0.05mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America
Product: Baraclude
Active Ingredient: Entecavir 0.5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America
Product: Baraclude
Active Ingredient: Entecavir 1mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America
Product: Brimonidine-AFT
Active Ingredient: Brimonidine tartrate 2mg/mL
Dosage Form: Eye drops, solution
New Zealand Sponsor: AFT Pharmaceuticals Limited
Manufacturer: Sterigen Inc, Upton, Quebec, Canada
Product: Carboplatin Ebewe
Active Ingredient: Carboplatin 10mg/mL
Dosage Form: Concentrate for injection
New Zealand Sponsor: Pharmaco (NZ) Limited
Manufacturer: EBEWE Pharma GmbH Nfg KG, Unterach am Attersee, Austria
Product: Octreotide
Active Ingredient: Octreotide acetate 0.05mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada
Product: Octreotide
Active Ingredient: Octreotide acetate 0.1mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada
Product: Octreotide
Active Ingredient: Octreotide acetate 0.5mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada
Dated this 15th day of September 2006.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go6543
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Risperdal Quicklet
Active Ingredient: Risperidone 2mg
Dosage Form: Orally disintegrating tablet
New Zealand Sponsor: Janssen-Cilag Pty Limited
Manufacturer: Janssen Ortho LLC, Mamey Ward, Gurabo, Puerto Rico
Dated this 15th day of September 2006.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go6542
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2006, No 109
Gazette.govt.nz —
NZ Gazette 2006, No 109
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare15 September 2006
Medicines, Distribution, New Medicines, Medicines Act 1981, Baraclude, Brimonidine-AFT, Carboplatin Ebewe, Octreotide
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare15 September 2006
Medicines, Distribution, Changed Medicine, Medicines Act 1981, Risperdal Quicklet
- DON MATHESON, Deputy Director-General, Public Health